Aurinia Early Urinary Protein Reduction Predicts Response

Lupus Nephritis Clinical Trial

— AURION  

Official title:

An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02949973
• Other study ID #: AUR-VCS-2014-01
• Status: Completed
• Phase: Phase 2
• Start date: June 2015
• Est. completion date: February 17, 2017

Study information

• Verified date: March 2021
• Source: Aurinia Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in patients with active lupus nephritis

Description:

Voclosporin is a novel calcineurin inhibitor (CNI) intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current development program is to investigate whether voclosporin added to the standard of care treatment in active Lupus Nephritis (LN) is able to reduce disease activity, as measured by a reduction in proteinuria. The background therapy will be mycophenolate mofetil (MMF) 2 g daily, initial treatment with IV methylprednisolone followed by a reducing course of oral corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 17, 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key Inclusion Criteria:

• Diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria (1997; see Appendix 6).

• Kidney biopsy within 24 months prior to screening with a histologic diagnosis of lupus nephritis International Society of Nephrology/Renal Pathology Society Classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in combination with Class III or IV.

• Laboratory evidence of active nephritis at screening, defined as: Class III, IV-S or Class IV-G (proteinuria =1000 mg/24 hours when assessed by 24 hour urine collection, defined by a urine protein/creatinine ratio (UPCR) of =1.0 mg/mg assessed in a first morning void urine specimen). Class V, alone or in combination with Class III or IV, (proteinuria =1,500 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of =1.5 mg/mg assessed in a first morning void urine specimen).

Key Exclusion Criteria:

• Estimated glomerular filtration rate (eGFR) as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation of =45 mL/min/1.73 m2 at screening

• Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.

• A previous kidney transplant or planned transplant within study treatment period.

• Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Subjects with cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been treated with conization or loop electrosurgical excision procedure, and have had a normal repeat Papanicolaou smear test (PAP) are allowed.

• Lymphoproliferative disease or previous total lymphoid irradiation.

• Severe viral infection (such as Cytomegalovirus (CMV), Hepatitis B virus (HBV), Hepatitis C virus (HCV)) within 3 months of screening; or known human immunodeficiency virus infection.

• Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

• Other known clinically significant active medical conditions, such as:

• Severe cardiovascular disease including congestive heart failure, history of cardiac dysrhythmia or congenital long QT syndrome. QT interval duration corrected for heart rate using method of Fridericia (QTcF) exceeding 480 msec in the presence of a normal QRS interval (<110 msec) at time of screening will result in exclusion.

• Liver dysfunction (aspartate aminotransferase, alanine aminotransferase, or bilirubin greater than 2.5 times the upper limit of normal) at screening and confirmed before enrollment.

• Chronic obstructive pulmonary disease or asthma requiring oral steroids.

• Bone marrow insufficiency unrelated to active systemic lupus erythematosus (SLE) (according to Investigator judgment) with white blood cell count <2,500/mm3; absolute neutrophil count <1.3 × 103/µL; thrombocytopenia (platelet count <50,000/mm3).

• Active bleeding disorders.

• Current infection requiring IV antibiotics.

Related Conditions & MeSH terms

• Lupus Nephritis
• Nephritis

Intervention

Drug:
• voclosporin

Locations

Country	Name	City	State
Malaysia	AURION Site	Kuala Lumpur
Malaysia	AURION Site	Kuala Lumpur

Sponsors (1)

Lead Sponsor	Collaborator
Aurinia Pharmaceuticals Inc.

Country where clinical trial is conducted

Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)		24 weeks
Primary	Number of Participants With Reduction or Normalization of Anti ds DNA		24 weeks
Primary	Number of Participants With Reduction or Normalization of C3		24 weeks
Primary	Number of Participants With Reduction or Normalization of C4		24 weeks
Secondary	Number of Participants With Complete Remission at Week 24	Confirmed Protein/creatinine ratio of =0.5 mg/mg and; eGFR = 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of =20%	week 24
Secondary	Number of Participants With Complete Remission at Week 48	Confirmed Protein/creatinine ratio of =0.5 mg/mg and; eGFR = 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of =20%; Safety Population - 2 subjects failed to provide sufficient data to ascertain week 48 response	week 48